United States · Platforms & data · Morningstar

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

Published by Morningstar · United States 8 h ago

The ASP-1929-181 study enrolled 19 patients with r/m HNSCC, and the long-term follow-up analysis included 17 efficacy-evaluable patients. Median overall survival (OS) was 28.2…

Read the full article on Morningstar Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

MarketBeat

JPMorgan Chase & Co. $JPM Stock Sold by Grandview Asset Management LLC

Seeking Alpha

France business activity deteriorates in October, missing consensus

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

The Motley Fool

Not Bitcoin. Not Ethereum. This Once-Popular Cryptocurrency Could Be the Biggest Winner of 2027.

Investing.com

Why is Crest Nicholson stock falling today?

Stocktwits